drugset
drugset / Trial / NCT01693640

A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome

NCT01693640 ↗

Phase 0 Completed 3 enrolled NYU Langone Health Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment

Summary

Hypothesis: Abatacept injections will decrease the number of oral ulcers seen in Behcet's patients

Timeline

Start
2012-06
Primary completion
2018-12-28
Completion
2018-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified 125 mg Other

Indications

Behcet disease